Back to Newsroom

Corbus Pharmaceuticals Reports Significant Improvement in mRSS and Other Clinical Outcomes at 28-Weeks in Systemic Sclerosis Open-Label Extension of Phase 2 Study

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, yesterday presented 6-month safety and efficacy data from the open-label extension (“OLE”) dosing in its ongoing Phase 2 study of anabasum (“JBT101-SSc-001”) in subjects with diffuse cutaneous systemic sclerosis (“SSc”). The results were presented at the American College of Rheumatology (“ACR”) Annual Meeting in San Diego, CA in a poster entitled: “Safety and Efficacy of Anabasum (JBT-101) in Diffuse Cutaneous Systemic Sclerosis (dcSSc) Subjects Treated in an Open-Label Extension of Trial JBT101-SSc-001.” To access the poster click here.
READ MORE…